Results 141 to 150 of about 23,251 (254)
Emergence of Two Rare Malignancies, Langerhans Cell Sarcoma and Myeloid Sarcoma, After Targeted Therapy for Chronic Lymphocytic Leukaemia: A Case Report. [PDF]
Niblock A, Mannion N, Sweeney K.
europepmc +1 more source
Simultaneous occurrence of chronic lymphocytic leukaemia and acute lymphoblastic leukaemia
J Bueno, MD Irriguible, C Palacio
doaj
Immune surveillance of residual leukemic stem cells after tyrosine kinase inhibitor discontinuation involves coordinated NK‐cell, CTL, Treg, pDC, and neutrophil activity that predicts treatment‐free remission, while exhausted CTLs and Treg expansion predict relapse in chronic myeloid leukemia.
Hiroshi Ureshino, Shinya Kimura
wiley +1 more source
The proposed mechanistic model in this study. ABSTRACT Noncoding RNAs, including circular RNAs (circRNAs), have been demonstrated to play vital roles in tumorigenesis. Uncovering the functions of circRNAs in tumorigenesis and their underlying regulatory mechanisms may suggest new approaches to the development of novel diagnostic and therapeutic ...
Yanfeng Liu, Yanan Gao, Chuanli Zhao
wiley +1 more source
Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma. [PDF]
Awan FT +8 more
europepmc +1 more source
CAR‐T therapy is evolving across four interconnected dimensions: functional engineering, manufacturing innovation, alternative cell sources, and in vivo CAR programming. Together, these advances address limitations in therapeutic efficacy, safety, manufacturing complexity, scalability, and accessibility, providing complementary paths toward the next ...
Yukimi Sakoda
wiley +1 more source
Chronic Lymphocytic Leukaemia (CLL)-Associated Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits (PGNMID) Diagnosed in the Absence of Detectable Paraprotein. [PDF]
Rodrigues F +4 more
europepmc +1 more source
BTK inhibition reprograms macrophages to suppress IL‐6/IL‐8/IL‐10‐driven CRS without compromising BsAb efficacy. ABSTRACT Bispecific antibodies (BsAbs) have shown marked efficacy in relapsed or refractory (R/R) B‐cell non‐Hodgkin lymphoma (B‐NHL). However, their clinical utility is constrained by cytokine release syndrome (CRS).
Jiaowu Cao +8 more
wiley +1 more source
Cost Effectiveness of First-Line Therapies for Treatment-Naïve Chronic Lymphocytic Leukaemia in South Africa. [PDF]
Woudberg R, Sinanovic E.
europepmc +1 more source

